Hormonal
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) reduce the risk of Heart Failure (HF) in a bodyweight-dependent manner, but also confer class-specific benefits beyond what is explained by weight or HbA1c changes alone.
If you have type 2 diabetes and are at risk for heart failure, SGLT2 inhibitors are the preferred class of medication. They reduce heart failure risk by 32% overall. This benefit comes from both weight loss (7% risk reduction per kg lost) and unique heart-protective effects that work even without significant weight change.
In meta-regression, every 1 kg bodyweight reduction, but not HbA1c reduction, was found to reduce the RR of HF by 7%... SGLT2i reduced HF more than could be explained by HbA1c or bodyweight reductions.
Why this rating
Meta-analysis of 35 RCTs with large sample size (256,524 patients) and specific subgroup analysis for SGLT2i.
Source
Efficacy of antihyperglycemic therapies on cardiovascular and heart failure outcomes: an updated meta-analysis and meta-regression analysis of 35 randomized cardiovascular outcome trials
Masashi Hasebe et al. · Cardiovascular Diabetology · 2023
DOI 10.1186/s12933-023-01773-z
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →